REM sleep suppression from long-term use disrupts the normal sleep pattern. REM sleep supports memory, learning, and mood regulation, so when REM is chronically reduced, sleep quality declines and daytime functioning can suffer. Therefore, the statement that long-term use can harm sleep due to REM sleep deprivation is true. Note that REM rebound can occur after stopping the use, but that is a separate response, not the ongoing effect during use.

Tolcapone carries a risk of liver toxicity, so signs of liver injury are the most concerning. Yellowing of the eyes and skin indicates jaundice, a telltale sign that bilirubin is building up because the liver isn’t processing it properly. This can progress to serious liver dysfunction, so it signals the need to stop tolcapone and promptly check liver function tests and bilirubin levels, then notify the clinician. Other listed side effects like nausea, dizziness, or headache can occur with many drugs and are typically less alarming, not signaling imminent severe harm the way jaundice does.

The main idea here is safe IV administration of diazepam during seizures. Diazepam given IV should be delivered through a sufficiently large vein and at a controlled rate to minimize irritation and potential complications. Administering into small veins is contraindicated because the IV solution contains solvents that can irritate fragile veins. Small veins are more prone to chemical phlebitis, vein inflammation, and tissue damage if extravasation occurs, especially with the propylene glycol solvent used in some IV diazepam formulations. This increases pain, swelling, and the risk of vein injury and complications at the injection site. In contrast, using a larger vein reduces irritation risk, and giving the drug slowly helps prevent respiratory depression and hemodynamic instability. Close monitoring of vital signs is essential during administration, and consulting a drug reference guide can help ensure correct dosing and precautions.

Older adults are particularly susceptible to central nervous system depressants, so the priority when starting cyclobenzaprine is monitoring sedation. This medication can cause drowsiness, dizziness, and slowed reaction times, and aging amplifies these effects because of changes in distribution, metabolism, and concurrent medications. If sedation becomes significant, the risk of falls, confusion, and impaired functioning increases substantially, making it essential to assess how sleepy or impaired the patient feels and to adjust the dose or discontinue if needed. This focused monitoring helps keep safety first, guiding decisions about activities, driving, and potential drug interactions with other sedatives or alcohol. While blood pressure, vision, and lung function are important in various clinical contexts, they are not the primary concerns with cyclobenzaprine initiation in an older adult compared to the direct impact of sedation on safety.